CPT® Code 81542

Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score

The CPT® Code 81542 pertains to a specific molecular genetic test utilized in oncology, particularly for prostate cancer. This test involves the analysis of messenger RNA (mRNA) extracted from formalin-fixed paraffin-embedded (FFPE) prostate tissue samples. The primary objective of this testing is to evaluate the expression of 22 specific genes that are relevant to prostate cancer progression. By employing microarray gene expression profiling, the test quantifies the levels of mRNA present in the tissue, which provides insights into the biological behavior of the cancer. The results of this analysis are crucial for predicting the likelihood of metastasis, especially in patients who have undergone radical prostatectomy. The test is particularly indicated for patients diagnosed with Stage 2 prostate cancer who have positive surgical margins, Stage 3 disease, or those exhibiting rising prostate-specific antigen (PSA) levels post-surgery. The algorithm developed from the genetic data yields a metastasis risk score ranging from 0 to 1, which aids healthcare providers in assessing the risk of clinical metastasis in patients experiencing biochemical recurrence after surgical intervention. Additionally, this risk score can inform decisions regarding the timing of postoperative radiotherapy, thereby playing a significant role in the management and treatment planning for prostate cancer patients.